Article

Cost of Goods Sold Analysis for Manufacturing mRNA-Based Cell and Gene Therapies

2026-05-06

Abstract excerpt

<h4>Background</h4> Cell and gene therapies (CGT) represent a transformative class of medical interventions, yet their high production costs limit patient access. Under-standing the structure of manufacturing costs is essential for informing policies that can expand access to these therapies. <h4>Objective</h4> This study develops and applies a cost-of-goods-sold (COGS) model to analyze the contributors to manuf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4054683d-06c5-5c44-a1ba-3f9e40cfa6c1
DOI: 10.64898/2026.05.04.26352406

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cost of Goods Sold Analysis for Manufacturing mRNA-Based Cell and Gene TherapiesDOI 10.64898/2026.05.04.26352406Read

Affordable mRNA Novel Proteins, Recombinant Protein Conversions and “Biosimilars”—Advice to Developers and Regulatory AgenciesSemantic proximity Read

Manufacturing Cell and Gene Therapies: Challenges in Clinical TranslationSemantic proximity Read

The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development ServicesSemantic proximity Read

GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forwardSemantic proximity Read

Financing covid-19 mRNA vaccinesSemantic proximity Read

Optimizing regulatory frameworks for gene therapies in rare diseases: Challenges and solutionsSemantic proximity Read

Patient, consumer and societal values, perceptions and preferences on high-cost gene therapiesSemantic proximity Read

Clinical trials to gene therapy development and production in Brazil: a reviewSemantic proximity Read

Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?Semantic proximity Read

Enabling mRNA Therapeutics: Current Landscape and Challenges in ManufacturingSemantic proximity Read

Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic DemandSemantic proximity Read

The Role of the Biomanufacturing Industry in Developing Diagnostics and mRNA Vaccines Against COVID-19Semantic proximity Read